ES3040063T3 - Combination of a protein kinase inhibitor and an additional chemotherapeutic agent - Google Patents

Combination of a protein kinase inhibitor and an additional chemotherapeutic agent

Info

Publication number
ES3040063T3
ES3040063T3 ES17823090T ES17823090T ES3040063T3 ES 3040063 T3 ES3040063 T3 ES 3040063T3 ES 17823090 T ES17823090 T ES 17823090T ES 17823090 T ES17823090 T ES 17823090T ES 3040063 T3 ES3040063 T3 ES 3040063T3
Authority
ES
Spain
Prior art keywords
compound
nci
etoposide
combination
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17823090T
Other languages
English (en)
Spanish (es)
Inventor
Lars Damstrup
Thomas Grombacher
Christian Sirrenberg
Lyubomir Vassilev
Astrid Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES3040063T3 publication Critical patent/ES3040063T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17823090T 2016-12-19 2017-12-18 Combination of a protein kinase inhibitor and an additional chemotherapeutic agent Active ES3040063T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436046P 2016-12-19 2016-12-19
PCT/EP2017/083272 WO2018114776A1 (en) 2016-12-19 2017-12-18 Combination of a protein kinase inhibitor and an additional chemotherapeutic agent

Publications (1)

Publication Number Publication Date
ES3040063T3 true ES3040063T3 (en) 2025-10-28

Family

ID=60915499

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17823090T Active ES3040063T3 (en) 2016-12-19 2017-12-18 Combination of a protein kinase inhibitor and an additional chemotherapeutic agent

Country Status (8)

Country Link
US (1) US11246929B2 (enExample)
EP (1) EP3554495B1 (enExample)
JP (1) JP7113826B2 (enExample)
KR (1) KR102607967B1 (enExample)
AU (1) AU2017384134B2 (enExample)
CA (1) CA3047449C (enExample)
ES (1) ES3040063T3 (enExample)
WO (1) WO2018114776A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JP7313492B2 (ja) * 2019-06-27 2023-07-24 メッドシャイン ディスカバリー インコーポレイテッド Ｄｎａ－ｐｋ阻害剤としてのキノリン及びシンノリン誘導体
CN116670128A (zh) * 2020-12-28 2023-08-29 南京明德新药研发有限公司 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
CN1861050A (zh) 2006-06-21 2006-11-15 山东蓝金生物工程有限公司 一种同载铂类化合物及其增效剂的抗癌药物缓释注射剂
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
SG188802A1 (en) 2008-03-06 2013-04-30 Genentech Inc Combination therapy with c-met and egfr antagonists
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정

Also Published As

Publication number Publication date
US20190365896A1 (en) 2019-12-05
AU2017384134B2 (en) 2022-03-24
KR102607967B1 (ko) 2023-11-29
CA3047449A1 (en) 2018-06-28
JP2020502182A (ja) 2020-01-23
EP3554495A1 (en) 2019-10-23
EP3554495B1 (en) 2025-06-04
WO2018114776A1 (en) 2018-06-28
AU2017384134A1 (en) 2019-08-01
KR20190099253A (ko) 2019-08-26
US11246929B2 (en) 2022-02-15
CA3047449C (en) 2023-07-04
JP7113826B2 (ja) 2022-08-05

Similar Documents

Publication Publication Date Title
US20210100813A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
RU2747788C2 (ru) Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака
US20210154198A1 (en) Combination therapy involving diaryl macrocyclic compounds
JP2020512977A (ja) Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
MXPA05001457A (es) Combinacion de inhibidores de tirosina cinasa del receptor del factor de crecimiento endotelial vascular para tratamiento de cancer.
ES3037447T3 (en) The compound of formula (i) and ponatinib for use in the treatment of chronic myeloid leukemia with bcr-abl mutations
TW200404532A (en) Therapeutic combinations of ERB B kinase inhibitors and antineoplastic therapies
EP4637774A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
CN114173785A (zh) 用于治疗非小细胞肺癌的氨基吡啶衍生物
US20100286038A1 (en) Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
JP7113826B2 (ja) プロテインキナーゼ阻害剤および追加的化学療法剤の組み合わせ
US20220323470A1 (en) Composition and use thereof in the manufacture of medicament for treating cancer
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
CN110638802A (zh) Atca在制备治疗肿瘤的药物中的用途
ES3017257T3 (en) Abt-751 and ionizing radiation for use in treating a brain tumor
RU2785997C1 (ru) Комбинация ингибитора протеинкиназы и дополнительного химиотерапевтического средства
TW202317128A (zh) 治療化療相關的胃腸道副作用的化合物和方法
HK40130580A (en) Cancer treatments using mta-cooperative prmt5 inhibitors
TW202434219A (zh) 使用乏氧激活化合物治療對parp抑制劑耐藥的患者的藥物及其製藥用途
Montagnoli et al. 136 Activity of the Cdc7 inhibitor NMS-1116354 as single agent and in combination in breast cancer models
Bischoff et al. 134 Biological characterization of ETP-46321 a potent and selective phosphoinositide-3-kinase inhibitor with antitumor activity
Smith et al. 135 Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of JNJ-26481585, a second generation histone deacetylase inhibitor
HK40061016A (en) Combination therapy for the treatment of uveal melanoma
NZ786604A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of